Quebecor Inc. announces stock split

Quebecor Inc. announces stock split

Canada NewsWire

MONTREAL, Nov. 8, 2017 /CNW Telbec/ - The Board of Directors of Quebecor Inc. (the « Corporation ») approved a two-for-one split of its outstanding Class A Multiple Voting Shares (the « Class A Shares ») and Class B Subordinate Voting Shares (the « Class B Shares »). The Corporation confirms that it has received the regulatory approval from the Toronto Stock Exchange (« TSX ») with respect to the stock split.

Accordingly, holders of Class A Shares and Class B Shares of the Corporation will receive one additional share for each share owned on the record date of November 15, 2017.  The payment date will be Thursday, November 16, 2017, the date from which the Corporation’s transfer agent AST Trust Company (Canada) (« AST ») will send promptly to registered shareholders residing in Canada a statement of Direct Registration System indicating the number of additional Class A Shares or Class B Shares, as the case may be, received as a result of the stock split. The registered shareholders residing outside Canada will receive a physical share certificate representing one additional share for each share held as of such record date. In addition, AST will electronically issue the appropriate number of Class A Shares and Class B Shares to CDS & Co for distribution to the non-registered shareholders.

The TSX has determined to implement the « due bill » trading procedure in connection with the split of the Class A Shares and Class B Shares. A due bill is an entitlement attached to listed securities undergoing a material corporate event, such as a stock split. In this case, anyone purchasing a Class A Share or a Class B Share of the Corporation during the period commencing one trading day before the record date, being Tuesday, November 14, 2017, and ending on the payment date, being Thursday, November 16, 2017 inclusively (the « due bill period »), will receive the entitlement attached to such securities.

The Class A Shares and the Class B Shares will commence trading on a « post-split » basis on Friday, November 17, 2017, as of which date purchases of the Corporation’s Class A Shares and Class B Shares will no longer have an attaching entitlement. The due bill redemption date is estimated to be Monday, November 20, 2017.

About Quebecor
Quebecor, a Canadian leader in telecommunications, entertainment, news media and culture, is one of the best-performing integrated communications companies in the industry. Driven by their determination to deliver the best possible customer experience, all of Quebecor’s subsidiaries and brands are differentiated by their high-quality, multiplatform, convergent products and services.

Quebecor (TSX: QBR.A, QBR.B) is headquartered in Québec. It holds an 81.53% interest in Quebecor Media, which employs more than 10,000 people in Canada.

A family business founded in 1950, Quebecor is strongly committed to the community. Every year, it actively supports more than 400 organizations working in the vital fields of culture, health, education, the environment and entrepreneurship.

Visit our website:
Follow us on Twitter:


SOURCE Quebecor

View original content:

CytRx Corporation Announces Reverse Stock Split

CytRx Corporation Announces Reverse Stock Split

Shares of Common Stock Will Begin Trading on a Post-Split Basis on November 1, 2017

PR Newswire

LOS ANGELES, Oct. 31, 2017 /PRNewswire/ – CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the previously disclosed 1-for-6 reverse stock split of its issued and outstanding common stock will become effective as of the commencement of trading on Wednesday, November 1, 2017 (the “Effective Time”).  The split-adjusted shares of CytRx’s common stock will continue trading on the Nasdaq Capital Market under the Company’s existing symbol “CYTR.”  A new CUSIP number of 232828608 has been assigned to the Company’s common stock as a result of the reverse split.

The reverse stock split will reduce the number of shares of common shares outstanding from approximately 165.8 million to approximately 27.6 million upon commencement of trading on the Effective Date.  Authorized shares will also be proportionally reduced from 250 million to approximately 41.7 million, and the preferred stock will be reduced from 5 million shares to approximately 0.8 million shares.  The reverse stock split affects all issued and outstanding shares of the Company’s Common Stock immediately prior to the Effective Time of the reverse stock split. 

At a Special Meeting of Stockholders held on October 27, 2017, the Company’s stockholders approved a proposal authorizing the Company to amend its certificate of incorporation and enact a 1-for-6 reverse stock split of the Company’s issued and outstanding shares.

American Stock Transfer and Trust Company, CytRx’s transfer agent, will instruct certificate shareholders on the exchange process once the reverse stock split takes effect.  Shareholders holding their shares in book-entry form or in brokerage accounts need not take any action in connection with the reverse stock split.  Beneficial holders are encouraged to contact their bank, broker or custodian with any procedural questions.  No fractional shares will be issued.  Stockholders who otherwise would be entitled to receive fractional shares because they hold a number of shares not evenly divisible by 6, will automatically receive one whole share of Common Stock in lieu of the fractional share.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical company specializing in research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor. Aldoxorubicin, CytRx’s most advanced drug conjugate, is an improved version of the widely used chemotherapeutic agent doxorubicin and has been out-licensed to NantCell, Inc.  CytRx is also rapidly expanding its pipeline of ultra-high potency oncology candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated Drug Release) technology platform, a discovery engine designed to leverage CytRx’s expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies.

Forward-Looking Statements

This press release contains forward-looking statements. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties relating to plans for regaining compliance with the Nasdaq rules and higher share price of our common stock; the ability of NantCell, Inc., to obtain regulatory approval for its products that use aldoxorubicin; the ability of NantCell, Inc., to manufacture and commercialize products or therapies that use aldoxorubicin; the amount, if any, of future milestone and royalty payments that we may receive from NantCell, Inc.; our ability to develop new ultra-high potency drug candidates based on our LADRTM technology platform; and other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx’s most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact: 
Argot Partners 
Michelle Carroll 
(212) 600-1902


View original content:

SOURCE CytRx Corporation

Global Caps & Closures by Region, Product and Market, 9th Edition

Global Caps & Closures by Region, Product and Market, 9th Edition

Advanced Products Drive Growth in Specialty Films Market

PR Newswire

NEW YORK, Oct. 30, 2017 /PRNewswire/ — Value gains will be driven by growing consumer preference for closures that offer convenience and ease-of-use advantages, as well as product safety features. The Asia/Pacific (despite significant deceleration in China) and Africa/Mideast regions will offer the fastest growth opportunities, while most developed markets will present more modest gains. However, advances through 2021 will generally decelerate from those of the 2011-2016 period, although growth in Eastern Europe will pick up. Bottled water will be the largest and fastest growing of the major applications for closures.

Read the full report:

Key Findings in the Global Caps & Closures Study

Plastic Caps and Closures Will Increase Their Already-Large Share of Demand
Plastic caps and closures will gain share primarily due to the shift in container mix generally favoring plastic over metal and glass. Plastic containers and closures offer a number of advantages, including lighter weight, reduced losses due to breakage, and a wider range of design options.
The declines of metal and glass are not universal, however. Metal closures retain a dominant share of the beer market in most regions, and metal screwcaps continue to grow in the wine market.

Bottled Water Leads Growth in Most Markets
Bottled water has become the leading closures market in unit terms. In developed markets, bottled water is viewed as a convenient on-the-go beverage option, and a healthier alternative to soft drinks and other more caloric beverage choices. In some developing areas, bottled water demand has been driven by substandard local water supplies, as well as rising personal incomes that have made bottled water a more accessible convenience.

Pharmaceutical Applications to Register Robust Growth
Gains in the pharmaceutical market will be driven by sustained growth in pharmaceutical output, as well as from ongoing efforts by drug makers to remain in compliance with government regulations and industry standards involving the child-resistant, senior-friendly, and security features of packaging systems. Growth in value terms will also benefit from increased use of high value-added dispensing and other functional closures that aid in the administration of oral liquid, topical, and other selected medicines.

Study Coverage
This study presents historical demand data (2006, 2011 and 2021) and forecasts for 2021by region, product (plastic, metal, rubber, and cork), and market (beverages, food, pharmaceuticals, and other). The study also evaluates company market share and provides analysis on industry competitors including Amcor, AptarGroup, BERICAP, Berry Global, Closure Systems International (Reynolds Group), Corticeira Amorim, Crown, Global Closures Systems (RPC Group), Guala Closures and Silgan.

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.  

Contact Clare:  
US: (339)-368-6001
Intl: +1 339-368-6001 

View original content:–closures-by-region-product-and-market-9th-edition-300545532.html

SOURCE Reportlinker